iCo Therapeutics (CVE:ICO), a biotech stock, rose after announcing that it will hold a pre IND meeting with the U.S. Food and Drug Administration (FDA)
Sean Mason | June 16, 2017 | SmallCapPower
A pre IND meeting with the U.S. Food and Drug Administration (FDA) was a dose of good news for a biotech stock Friday. Here’s some small stocks making big moves on Friday, June 16, 2017 (as of 4 pm EST):
iCo Therapeutics (TSXV: ICO), a biotech stock, climbed 25% to $0.05 on Friday after announcing that it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, U.S. Food and Drug Administration (FDA) on June 21, 2017, in which discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure.
As well, shares of Prometic Life Sciences Inc. (TSX: PLI) slipped 11% to $1.65 as the biopharmaceutical company said it has entered into a $53.125 million bought-deal financing agreement at a price of $1.70 per share.
dynaCERT Inc. (TSXV: DYA), meanwhile, reported that it has signed multiple dealership agreements in Europe, in which the dealers will stock and resell the HydraGEN products in their local markets. dynaCERT stock moved up as much as 9% before ending 3% higher at $0.82 following the announcement.
Finally, ID Watchdog, Inc. (TSXV: IDW) shares powered 70% higher to $0.51 after the provider of consumer-facing identity theft protection and resolution services announced that it has agreed to be acquired by a subsidiary of Equifax Inc. for US$63,335,000 in cash, or about US$0.40 per share.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: